This article is more than 5 years old. Information may no longer be current.

Alimera reports 188% increase in net revenue in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported $6.9 million in net revenue in the third quarter, a 188% increase compared with $2.4 million reported in the same quarter of 2014, according to a press release.

The increase was primarily attributed to the launch of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) in the U.S.

Sales and marketing expenses were reported at $6.9 million in the third quarter compared with $3.5 million in the same quarter of 2014.

GAAP net loss applicable to common stockholders was reported at $1.5 million, or $0.03 per basic and diluted share, in the third quarter compared with $7 million, or $0.17 per basic and diluted share, in the same quarter of 2014.